4D Molecular Therapeutics, Inc. FDMT 深 沪
等待开盘 02-03 09:30:00 美东时间
9.15
+0.290
+3.27%
华盛通- 最 高9.375
- 今 开8.73
- 成交量 76.85万股
- 最 低 8.60
- 昨 收 8.86
- 总市值 5.23亿
- 52周最高 12.34
- 市盈率 静 --
- 换手率 1.35%
- 52周最低 2.235
- 委 比 -83.08%
- 总股本 5713.51万
- 历史最高 55.11
- 量 比 0.93
- 振 幅 8.75%
- 历史最低 2.235
- 每 手 1
- 风险率 2.73%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多4D Molecular Therapeutics Issues Pre-Funded Warrants in Exchange for Common Stock
4D Molecular Therapeutics Issues Pre-Funded Warrants in Exchange for Common Stock 4D Molecular Therapeutics Inc. has announced the issuance of pre-funded warrants in exchange for common stock through unregistered sales to RA Capital Healthcare Fund, L.P. and Biotechnology Value Fund, L.P. and its af
01-27 05:06
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics, a late-stage biotech company, announced that on January 13, 2026, its compensation committee granted four new non-executive employees 23,600 Restricted Stock Units (RSUs) under its 2025 Employment Inducement Award Plan. The company is advancing innovative therapeutics, including 4D-150 for treating retinal diseases and 4D-710 as a potential CFTR gene therapy for cystic fibrosis. Both products remain in clinical developm...
01-17 13:00
4DMT Provides Company Update and Anticipated Development Milestones for 2026
4D分子治疗公司宣布其4D-150湿性AMD III期临床试验入组人数超出预期，4FRONT-1试验预计将于2026年第一季度完成入组，截至2026年1月6日已有381名患者入组。PRISM IIb期数据和SPECTRA I/II期数据分别预计于2026年中和下半年公布。此外，公司任命Glenn Sblendorio为董事会成员，并计划于2026年1月14日在J.P. Morgan健康大会上展示战略展望。公司现金流充足，支持未来开发计划至2028年中。
01-07 13:00
美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
2025-12-19 10:15
4D Molecular Therapeutics Says Interim Data From 4D-710 Phase 1 AEROW Trial For Cystic Fibrosis Lung Disease Shows Meaningful Lung Function Activity
Clinically meaningful lung function activity, measured by ppFEV1 and LCI2.5, with follow-up through 1 year at dose selected for Phase 2 Durable CFTR transgene expression within target therapeutic range with
2025-12-17 20:03
4DMT Announces New Employment Inducement Grants
4DMT, a late-stage biotechnology company, announced the grant of 13,800 Restricted Stock Units to three new non-executive employees under its 2025 Employment Inducement Award Plan. The company is focused on advancing durable and disease-targeted therapeutic candidates, such as 4D-150 for treating blinding retinal vascular diseases, and 4D-710 for cystic fibrosis. All product candidates are in clinical or preclinical development and have not yet r...
2025-12-12 21:05
4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference
4D Molecular Therapeutics will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 7:30 a.m. PT. The presentation will include updates on the company's lead product candidate 4D-150, currently in Phase 3 development for wet age-related macular degeneration, and its second candidate 4D-710 for cystic fibrosis. A webcast will be available live and archived for one year on the company's investor website.
2025-12-08 13:00
4DMT to Participate in 8th Annual Evercore Healthcare Conference
4D Molecular Therapeutics announced that its management team will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 3, 2025, at 2:35 p.m. ET. The company, focused on developing innovative therapeutics for blinding retinal vascular diseases and cystic fibrosis, will also offer one-on-one meetings. Its lead product, 4D-150, is in Phase 3 for wet age-related macular degeneration, and 4D-710 targets cystic fi...
2025-11-20 13:00
4D Molecular Therapeutics taps Kristian Humer as CFO
4D Molecular Therapeutics (FDMT) has appointed Kristian Humer as chief financial officer. Humer is a seasoned finance executive and biotechnology leader with more than two decades of experience, inclu...
2025-11-17 19:17
4DMT Appoints Kristian Humer as Chief Financial Officer
4D Molecular Therapeutics任命Kristian Humer为首席财务官，负责财务策略和运营。Humer在金融和生物技术领域拥有超过20年的经验，曾担任Citi的医疗投资银行业务负责人，并担任多家公开上市公司 CFO。此次任命正值公司推进多个III期临床项目及准备商业化之际。公司CEO David Kirn表示，Humer的专业背景将助力4DMT实现长期增长和价值最大化。Humer表示期待与团队合作，推动公司的财务和战略发展。
2025-11-17 11:00
